Pathological complete response and accelerated drug approval in early breast cancer.

Neoadjuvant trials introduce new drugs preoperatively in patients with localized breast cancer, using the rate of pathological complete response as the primary end point. The FDA has issued guidance for using this end point in applying for accelerated drug approval.

[1]  H. El‐Serag,et al.  Insurance status and treatment candidacy of hepatitis C patients: Analysis of population‐based data from the United States , 2011, Hepatology.

[2]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[3]  Preoperative chemotherapy for women with operable breast cancer. , 2007, The Cochrane database of systematic reviews.

[4]  Rachel S Tocco,et al.  Public health impact of antiviral therapy for hepatitis C in the United States , 2009, Hepatology.

[5]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[6]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[7]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.